

Case Report

Visceral Leishmaniasis and Herpes Zoster as a Component of Syndrome of Immune Reconstitution Inflammatory Syndrome in an HIV-Positive Patient

Ermira Muço,1 Arta Karruli,1,2 Neada Hoxha,1 Alma Hoxhaj,1 and Majlinda Kokici3

1Department of Infectious Diseases, Hospital University Center "Mother Theresa", Tirana, Albania
2Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
3Service of Laboratory, Hospital University Center "Mother Tereza", Tirana, Albania

Correspondence should be addressed to Ermira Muço; ermiramuco@yahoo.com

Received 23 December 2021; Revised 20 February 2022; Accepted 28 February 2022; Published 14 March 2022

Academic Editor: Mohamed A. Dkhil

Copyright © 2022 Ermira Muço et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Immunereconstitution syndromes (IRIS) are a state of unusual hyperinflammatory response against latent infections which occurs after CD4 cell count improvement and as a consequence of immune response once highly active antiretroviral therapy for HIV is introduced. Leishmania parasites and varicella zoster virus (VZV) may be a manifestation of IRIS, but few data exist in literature in particular regarding Leishmania parasites. Case Presentation. A 47-year-old man was admitted to our hospital with fever. He was diagnosed with HIV infection and was a late presenter according to CD4+ count of 98 cells/mm³/9.5% and baseline illness (chronic diarrhea, weight loss, and oral candidiasis). He started highly active antiretroviral therapy (abacavir plus lamivudine plus efavirenz). The patient started treatment with liposomal amphotericin B. He presented with disseminated herpes zoster infection. CD4+ count was 28.5%, 455 cells/mm³. The patient started treatment with acyclovir for 10 days. Four weeks later, he had no skin elements. At present, the patient continues HAART and is under regular monitoring. Conclusions. Early diagnosis of IRIS-associated diseases and treatment were fundamental in the patient’s prognosis. Our patient presented with two different components of IRIS in two different time frames, confirming IRIS to be a broad-spectrum disease, heterogeneous and unique for each patient. A close monitoring during ART initiation, in particular in late presenters, is important in preventing IRIS. In cases of IRIS development, a detailed investigation of rare associated diseases not only common ones is of great importance for the management and the prognosis of these patients.

1. Introduction

IRIS is a potential complication of highly active antiretroviral therapy (HAART). It was first reported in the 1990s. Following the initiation of HAART, however, there is an anticipated improvement in the immune-mediated inflammatory response. This unusual hyperinflammatory response is the trademark of IRIS. The prevalence of IRIS is likely to increase with the increasing use of HAART in human immunodeficiency virus (HIV)-infected patients. A few studies reported that up to 25–30% of HIV patients on antiretroviral therapy had IRIS [1, 2]. The clinical presentation depends on the underlying pathogen, organ/system involved, and the severity of the inflammatory response [3]. IRIS usually occurs within 6 months of initiation of antiretroviral therapy (ART) in patients with low CD4+ counts and can occur before any marked elevation in CD4+ count is achieved on HAART [4]. The spectrum of infections associated with IRIS is expanding and now includes a number of parasitic infections, which may be mediated by different immunopathological mechanisms. Cases of IRIS with visceral leishmaniasis (VL) have been reported [5].
difficulties to be detected by routine diagnostic tests, and most often results in an unfavorable response to treatment, frequent relapses, and in premature deaths [6]. The coinfection Leishmania-HIV is frequent in the Mediterranean area [7] and more frequent in immunosuppressed patients (CD4 count <200 mm³) [7]. Mucocutaneous HZ accounts for 7–12% of the diseases related to HIV infection and can reactivate again when the subject’s immunity improves from the administration of HAART. It usually occurs after 4 weeks from the initiation of HAART, and under these circumstances, the clinical symptoms and natural course of mucocutaneous HZ are similar to those in HIV-seropositive subjects who do not manifest IRIS [8].

2. Case Presentation

A 47-year-old male was diagnosed with HIV infection, stage C3, HIV-RNA was $2.4 \times 10^4$, and CD4(+) count was 98 cells/mm³/9.5% at our infectious disease service of Mother Theresa Hospital, Tirana, Albania. The medical history of the patient was positive for oropharyngeal candidiasis, chronic diarrhea, and weight loss. The patient started ARV treatment, abacavir plus lamivudine plus efavirenz. He presented 88 days later with a 17-day history of high fever (39–40°C), sweat, fatigue, further weight loss, and lethargy. Physical examination revealed inguinal, cervical, and axillary lymphadenopathy and distended abdomen with hepatomegaly 3 cm and splenomegaly 4 cm under the costal margin. Hematocchemical parameters showed pancytopenia: white blood cells $1.7 \times 10^3$/mm³, red blood cells $2.66 \times 10^6$ cells/mm³, hemoglobin 7.8 g/dl, hematocrit 22.3%, platelet count $1.31 \times 10^9$ cells/mm³, lymphocyte count 51.8%, monocyte count 6.5%, and granulocyte count 41.7%. Other hematocchemical parameters resulted as follows: C-reactive protein 117 mg/l, fibrinogen 554 mg/dl, the protein electrophoresis showed gamma globulin 36.1%, and albumin, 44.7%. Serological markers for *Toxoplasma gondii*, *Cytomegalovirus*, *Salmonella*, *Brucella*, hepatitis A and B viruses, and Epstein–Barr virus were negative. Autoimmune diseases were excluded. Bone marrow aspiration finally identified the presence of Leishmania (Figures 1(a) and 1(b)). IFAT and the rapid immunochromatography test-rK39 were positive. Ultrasonography examination revealed hepatosplenomegaly (liver 18 cm, spleen 19 × 10 cm). Investigation of the immune system showed CD4+ T lymphocyte count 22%, 374 cells, and CD8 T cells 61%. HIV-RNA was undetectable.

The first cycle of liposomal amphotericin B (at a dose of 3–5 mg/kg/day) course was administered immediately for 5 days resulting in clinical and hematocchemical parameters improvement (white blood cells $3 \times 10^3$ cells/mm³, red blood cells $3.7 \times 10^6$ cells/mm³, and platelet count $1.86 \times 10^5$ cells/mm³). Combined amphotericin B and corticosteroid treatments were well-tolerated. Liposomal amphotericin B was administered again on days 10, 17, 24, 31, and 38. His general condition was both clinically and biologically stable. After 105 days under ARV medication, he presented to our hospital with maculopapular lesions that progressed into vesicles and then pustules and crusts on the right thoracic region with dermatomes C5, C6, C7, C8, and T1 (Figure 2). He was diagnosed with herpes zoster. The patient was treated with acyclovir for ten days. CD4 count was 28.5%, 455 cells. After four weeks, he had no elements in the skin, as shown in Figure 3. The patient did not develop postherpetic neuralgia. At present, the patient continues treatment with ART and is under regular monitoring. His life quality has improved significantly.

3. Discussion

Since the identification of the first HIV/AIDS case in Albania in 1993, 1430 HIV-positive persons have been diagnosed. 749 people receive ARV treatment. There have been publications about AIDS cases, but few data exist about IRIS; this complication is related to HAART. Immune reconstitution inflammatory syndrome (IRIS), also known as immune restoration disease, refers to a disease or pathogen-specific inflammatory response in HIV-infected patients that may be triggered after initiation or reinitiation of highly active antiretroviral therapy (HAART) or change to more active HAART therapy. The risk of IRIS is mainly associated with severe immunosuppression at the start of HAART [9, 10]. Our patient began HAART therapy at an advanced stage of immunodeficiency with HIV-RNA of $2.4 \times 10^4$ and CD4(+).
count of 98 cells/mm³, 9.5%. Males were more at risk of developing IRIS [11]. Also, the rate of HIV infection is higher in males compared to females [12]. The spectrum of infections now recognized as associated with IRIS is expanding and includes a number of parasitic infections, which may be mediated by different immunopathological mechanisms. Here, we included also visceral leishmaniasis [5]. Visceral leishmaniasis (VL) is a common opportunistic infection in HIV-positive patients from endemic countries but occurs rarely following antiretroviral treatment [13]. It is a vector-borne infection that is transmitted to humans through the bite of an infected sandfly which usually becomes infected from blood of infected animals in particular dogs. Clinical symptoms mostly include fever, weight loss, liver, and spleen enlargement which were found in our case as well. Albania is an endemic country for Leishmania [14]. In 2014, Badaro et al. noted that 34 cases of leishmaniasis as a manifestation of IRIS have been described worldwide [15]. The mean time between the onset of HAART and the occurrence of leishmaniasis IRIS-related manifestations was 6 days to 11 months [16, 17]. The interval between beginning of HAART and the onset of IRIS was 88 days in our case with VL. Mean onset of disease from ART initiation was 5 weeks (range 1–17 weeks), and no cases with varicella zoster occurred before 4 weeks of therapy [18, 19]. The interval between beginning of HAART and the onset of IRIS was 105 days in our case with VZ. IRIS is usually accompanied by an increase in CD4 cell count and/or a rapid decrease in viral load. CD4+ T lymphocyte count was 22%, 374 cells/mm³ when VL manifested, and CD4+ count was 28.5%, 455 cells/mm³ when VZ manifested. HIV-RNA was undetectable in our case. Significant increases in CD8 T cells are a risk factor for developing dermatomal zoster. We noticed in our patient an increase of CD8 T cells up to 61%. The pentavalent antimonials still remain the first line of therapy for coinfected cases. However, amphotericin B, especially the liposome formulation, the active component of AmBisome, was found to be relatively less toxic and more potent compared to pentamidine [6]. The cycle of liposomal amphotericin B course was administered immediately for 5 days which improved clinical and hematocultural parameters of our patient. Liposomal amphotericin B proved to be effective and safe in our case. No adverse event was observed. Combined amphotericin B and corticosteroid treatments were well-tolerated. Currently, new compounds are being studied such as curcumin, which showed great antileishmanial activity [20]. When the patient developed VZ, he was treated with oral acyclovir which also significantly improved the clinical situation.

4. Conclusion
Our patient was diagnosed as late presenter HIV, and since IRIS in HIV is associated with important immune system depletion at ART start, IRIS in our patient manifested not only with Herpes Zoster but also with visceral leishmaniasis, a less common IRIS-associated condition. Our patient presented with two different components of IRIS in two different time frames, confirming IRIS to be a broad-spectrum disease heterogeneous and unique for each patient.
Early diagnosis and treatment were fundamental in the patient’s prognosis. A close monitoring during ART initiation, in particular, in late presenters is important in preventing IRIS. In case of IRIS development, a detailed investigation of rare associated diseases not only common ones is of great importance for the management and the prognosis of these patients.

Data Availability
No data were used to support this study.

Consent
Written informed consent was obtained from the patient for the publication of this case report and any accompanying images.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
EM conceived and drafted the manuscript. AK designed and revised the work. MK participated in the design of the study and performed the laboratory analysis. NH and AH critically revised the manuscript. All authors read and approved the final manuscript.

References
[1] S. Bosamiya, “The immune reconstitution inflammatory syndrome,” Indian Journal of Dermatology, vol. 56, no. 5, pp. 476–479, 2011.
[2] S. Sharma and M. Soneja, “HIV & immune reconstitution inflammatory syndrome (IRIS),” Indian Journal of Medical Research, vol. 134, no. 6, pp. 866–877, 2011.
[3] N. F. Walker, J. Scriven, G. McIntjes, and R. J. Wilkinson, “Immune reconstitution inflammatory syndrome in HIV-infected patients,” HIV/AIDS (Auckland, N.Z.), vol. 7, pp. 49–64, 2015.
[4] I. Sereti, “Immune reconstitution inflammatory syndrome in HIV infection: beyond what meets the eye,” Topics in antiviral medicine, vol. 27, no. 4, pp. 106–111, 2020.
[5] S D Lawn and R J Wilkinson, “Immune reconstitution disease associated with parasitic infections following antiretroviral treatment,” Parasite Immunol, vol. 28, no. 11, pp. 625–33, 2006.
[6] A. Ahmed, “Leishmaniasis and HIV/AIDS co-infections: review of common features and management experiences,” Ethiopian Medical Journal, vol. 40, pp. 37–49, 2002.
[7] A. Moreno-Camacho, R. López-Vélez, A. Muñoz Sanz, and P. Labarga-Echevarria, “Intestinal parasitic infections and leishmaniasis in patients with HIV infection,” Enfermedades Infecciosas y Microbiología Clínica, vol. 16, pp. 52–60, 1998.
[8] L. Feller, H. Wood, N. H. Wood, and J. Lemmer, “Herpes zoster infection as an immune reconstitution inflammatory syndrome in HIV-seropositive subjects: a review,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology & Endodontics, vol. 104, no. 4, pp. 455–460, 2007.
[9] M. Müller, S. Wandel, R. Colebunders, S. Attia, H. Furrer, and M. Egger, “Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis,” The Lancet Infectious Diseases, vol. 10, no. 4, pp. 251–261, 2010.
[10] S. Sharma and M. Soneja, “HIV & immune reconstitution inflammatory syndrome (IRIS),” Indian Journal of Medical Research, vol. 134, no. 6, pp. 866–877, 2011.
[11] D. M. Murdoch, W. D. Venter, A. van Rie, and C. Feldman, “Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options,” AIDS Research and Therapy, vol. 4, no. 1, p. 9, 2007.
[12] “Center for Disease control and Prevention,” HIV, https://www.cdc.gov/hiv/group/gender/men/index.html.
[13] B. T. Schlevevoigt, R. Ignatius, M. Baier et al., “Development of visceral leishmaniasis in an HIV+ patient upon immune reconstitution following the initiation of antiretroviral therapy,” Infection, vol. 44, no. 1, pp. 115–119, 2016.
[14] Centers for Disease control and Prevention, “Leishmaniasis,” https://www.cdc.gov/leishmaniasis/index.html.
[15] R. Badaró, L. O. Gonçalves, L. L. Gois, Z. P. G. Maia, C. Benson, and M. F. R. Grassi, “Leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients,” Journal of the International Association of Physicians in AIDS Care, vol. 14, no. 5, pp. 402–407, 2015.
[16] A. Berry, B. Abraham, J. Dereure, V. Pinzani, P. Bastien, and J. Reynes, “Two case reports of symptomatic visceral leishmaniasis in AIDS patients concomitant with immune reconstitution due to antiretroviral therapy,” Scandinavian Journal of Infectious Diseases, vol. 36, no. 3, pp. 225–227, 2004.
[17] M. Alsina-Gibert, I. López-Lerma, and E. Martinez-Chamorro, “Cutaneous manifestations of visceral leishmaniasis resistant to liposomal amphotericin B in an HIV-positive patient,” Archives of Dermatology, vol. 142, no. 6, pp. 787–789, 2006.
[18] P. Domingo, O. H. Torres, J. Ris, and G. Vazquez, “Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection,” The American Journal of Medicine, vol. 110, no. 8, pp. 605–609, 2001.
[19] E. Martinez, J. Gatell, Y. Moran et al., “High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors,” Clinical Infectious Diseases, vol. 27, no. 6, pp. 1510–1513, 1998.
[20] M. Elamin, E. Al-Olayan, R. Abdel-Gaber, and R. S. Yehia, “Anti-proliferative and apoptosis induction activities of curcumin on Leishmania major,” Revista Argentina de Microbiología, vol. 53, pp. 240–247, 2020.